METTL21A Antibody

What is METTL21A and what cellular functions is it involved in?

METTL21A (Methyltransferase-like protein 21A) functions as a protein-lysine methyltransferase that specifically trimethylates lysine residues in heat shock protein 70 (HSP70) family members . This enzyme belongs to the methyltransferase superfamily, specifically within the METTL21 family . METTL21A contributes significantly to the in vivo trimethylation of lysine residues in HSPA1 and HSPA8, which are critical heat shock proteins involved in protein folding and cellular stress responses .

The protein exhibits specific enzymatic activity toward several HSP70 family members. In vitro studies have demonstrated that METTL21A methylates 'Lys-561' in HSPA1, 'Lys-564' in HSPA2, 'Lys-585' in HSPA5, 'Lys-563' in HSPA6, and 'Lys-561' in HSPA8 . This selective targeting capability indicates METTL21A's specialized role in modifying heat shock proteins that are involved in diverse cellular processes including protein quality control, stress response, and protein homeostasis mechanisms.

METTL21A is also known by several alternative names in the literature, including FAM119A, HCA557B, HSPA lysine methyltransferase (HSPA-KMT), Hepatocellular carcinoma-associated antigen 557b, and Protein N-lysine methyltransferase METTL21A . These multiple designations reflect its identification through different research approaches and its various functional contexts.

What is the significance of METTL21A in cancer research?

Recent research has revealed that METTL21A may function as a tumor suppressor in certain cancer types, notably in pancreatic ductal adenocarcinoma (PDAC) . Meta-analysis of publicly available gene expression datasets has demonstrated that METTL21A is significantly downregulated in PDAC compared to normal tissue . Furthermore, reduced expression of METTL21A correlates with poor patient survival, suggesting its potential clinical relevance as a prognostic biomarker .

Cellular studies further corroborate these findings, as knockdown of METTL21A in human PDAC cell lines leads to robust increases in cell proliferation, enhanced colony formation in vitro, and accelerated xenograft growth in vivo . Conversely, ectopic expression of wild-type METTL21A, but not enzyme-dead mutants, significantly impairs growth in both in vitro and in vivo contexts . These findings collectively underscore METTL21A's potential significance as a therapeutic target and prognostic marker in pancreatic cancer research.

What applications are METTL21A antibodies suitable for?

METTL21A antibodies are suitable for several important research applications, with immunohistochemistry on paraffin-embedded sections (IHC-P) being a validated primary application . Commercial antibodies, such as the mouse monoclonal anti-METTL21A antibody (OTI2G7), have been specifically tested and confirmed effective for IHC-P applications with human tissue samples . This application is particularly valuable for analyzing METTL21A expression patterns in normal tissues versus pathological specimens.

The validated applications of METTL21A antibodies have been demonstrated in various tissue contexts. For instance, paraffin-embedded human pancreas tissue has been successfully stained for FAM119A (alternative name for METTL21A) using specific dilution parameters (1/150) in immunohistochemical analyses . Similar protocols have been applied to carcinoma of human lung tissue, suggesting the antibody's utility across multiple tissue types .

While IHC-P represents a well-established application, researchers should be aware that antibody validation for other techniques may vary. When selecting METTL21A antibodies for specific applications, it's crucial to verify that the particular species and application combination has been tested and validated by the manufacturer to ensure reliable results . For novel applications, preliminary optimization experiments should be conducted to establish appropriate conditions.

How can METTL21A antibodies be used to study its role in tumor suppression?

Studying METTL21A's tumor suppressor role requires sophisticated antibody-based approaches that can detect both expression levels and functional aspects of the protein. Immunohistochemistry with METTL21A antibodies provides a valuable method for examining expression patterns in normal versus cancerous tissues, as demonstrated in pancreatic cancer studies that revealed significant downregulation in tumor specimens . When conducting such analyses, researchers should employ heat-induced epitope retrieval methods (e.g., 10mM citric buffer, pH6.0, 100°C for 10 minutes) to ensure optimal antigen detection .

For mechanistic studies of METTL21A's tumor suppression activity, researchers can utilize antibodies to compare wild-type versus enzyme-dead mutant protein effects. This approach has proven crucial in demonstrating that METTL21A's tumor suppression depends on its enzymatic activity, as ectopic expression of wild-type but not enzyme-dead mutant METTL21A impaired growth in PDAC models . This methodology requires antibodies that recognize conserved epitopes present in both wild-type and mutant proteins.

Researchers can also integrate METTL21A antibody detection with functional assays measuring cellular proliferation, colony formation, and in vivo tumor growth to correlate expression levels with phenotypic outcomes . When designing such studies, careful consideration should be given to antibody specificity and the potential cross-reactivity with other METTL21 family members. Western blotting verification prior to immunohistochemical studies is advisable to confirm antibody specificity in the experimental system.

What methodologies are effective for detecting METTL21A methyltransferase activity?

Detecting METTL21A methyltransferase activity requires specialized methodologies that go beyond simple protein expression analysis. A powerful approach combines in vitro methylation assays with mass spectrometry analysis to identify specific methylation sites on target proteins . This technique has successfully identified HSPA1 and HSPA8 as substrates for METTL21A, revealing specific lysine residues that undergo trimethylation .

For in vivo assessment of METTL21A activity, researchers can employ methylation-specific antibodies that recognize trimethylated lysine residues on HSP70 family proteins. This approach allows for the detection of endogenous methylation events in cellular contexts and can be combined with METTL21A knockdown or knockout studies to establish causal relationships . When implementing this methodology, careful validation of methylation-specific antibodies is essential to ensure they recognize only the trimethylated state of the specific lysine residue of interest.

Comparing methylation levels between wild-type cells and those expressing catalytically inactive METTL21A mutants provides another effective strategy. This approach requires site-directed mutagenesis to generate enzyme-dead variants while maintaining protein expression and stability . Researchers should carefully design experiments to include appropriate controls and quantitative methods for measuring methylation levels, such as quantitative mass spectrometry or densitometric analysis of western blots using methylation-specific antibodies.

How can researchers validate METTL21A knockout models?

Validating METTL21A knockout models requires a multi-faceted approach to confirm complete elimination of the protein and its enzymatic activity. Researchers have successfully generated global knockout mouse models using CRISPR/Cas9 technology, as demonstrated in studies examining METTL21A's role in spermatogenesis . When establishing such models, comprehensive validation at both genomic and protein levels is essential.

At the genomic level, PCR-based genotyping should confirm the targeted disruption of the Mettl21a gene. This can be complemented by sequencing to verify the exact nature of the introduced mutation . At the protein level, western blotting with validated anti-METTL21A antibodies is crucial to confirm the absence of protein expression in knockout tissues compared to wild-type controls .

Functional validation involves examining the methylation status of known METTL21A targets, particularly HSP70 family members. Mass spectrometry analysis can confirm the absence of specific trimethylation marks, such as at Lys-561 in HSPA1 or Lys-561 in HSPA8 . Additionally, researchers should assess potential compensatory mechanisms by examining the expression and activity of other METTL21 family members (METTL21B-E) that might become upregulated in response to METTL21A loss . This comprehensive validation approach ensures that observed phenotypes can be confidently attributed to METTL21A deficiency.

What are the optimal protocols for using METTL21A antibodies in immunohistochemistry?

Optimal immunohistochemistry (IHC) protocols for METTL21A detection require careful attention to several critical parameters. Based on validated approaches, researchers should use paraffin-embedded tissue sections and implement heat-induced epitope retrieval methods for maximum sensitivity . A recommended protocol involves using 10mM citric buffer (pH6.0) at 100°C for 10 minutes to effectively unmask antigens that may be obscured during fixation and embedding processes .

For primary antibody incubation, a dilution of 1/150 has been successfully applied with commercial anti-METTL21A antibodies such as the mouse monoclonal antibody OTI2G7 . This dilution provides optimal signal-to-background ratio in human tissue samples, including pancreas and lung tissues . Incubation periods typically range from 1-2 hours at room temperature or overnight at 4°C, although specific optimization may be necessary depending on tissue type and fixation conditions.

Detection systems should be selected based on the primary antibody species, with appropriate secondary antibodies conjugated to enzymes like horseradish peroxidase (HRP) for chromogenic detection. For enhanced sensitivity in tissues with low METTL21A expression, polymer-based detection systems or tyramide signal amplification methods may be employed. Counterstaining with hematoxylin provides nuclear context, allowing proper localization of METTL21A staining within cellular compartments. Each new antibody lot should undergo validation with positive and negative control tissues to ensure consistent performance across experiments.

How can researchers differentiate between wild-type and enzyme-dead METTL21A?

Differentiating between wild-type and enzyme-dead METTL21A presents a methodological challenge that requires specialized approaches. Since enzyme-dead mutants maintain protein structure while losing catalytic function, conventional antibody-based detection cannot distinguish between these variants . Instead, researchers must employ functional assays that measure methyltransferase activity.

A recommended approach combines expression studies with activity assays. First, researchers can introduce tagged versions of wild-type or mutant METTL21A into cellular systems, confirming equal expression levels through western blotting with anti-METTL21A antibodies . Subsequently, methyltransferase activity can be assessed by examining the methylation status of known METTL21A substrates, particularly lysine residues in HSP70 family proteins (e.g., 'Lys-561' in HSPA1, 'Lys-561' in HSPA8) .

For precise quantification of methyltransferase activity, in vitro methylation assays using recombinant METTL21A proteins (wild-type versus mutant) can be performed with purified HSP70 substrates . These assays utilize radioactively labeled methyl donors (S-adenosyl-L-methionine) or non-radioactive alternatives that allow direct measurement of methyl transfer. Mass spectrometry analysis provides the most definitive approach, enabling precise identification and quantification of site-specific methylation on target proteins, clearly distinguishing the functional consequences of wild-type versus catalytically inactive METTL21A variants .

What approaches are recommended for studying METTL21A in different tissue contexts?

Studying METTL21A across diverse tissue contexts requires tailored methodological approaches that account for tissue-specific expression patterns and functional roles. Multi-tissue expression analysis should first be conducted to identify tissues with significant METTL21A expression . Western blotting and quantitative PCR can establish baseline expression levels across tissues, guiding subsequent focused investigations.

For tissues with high endogenous METTL21A expression, such as testes, immunohistochemistry using validated antibodies provides valuable insights into cellular and subcellular localization patterns . Optimized protocols should be developed for each tissue type, with particular attention to fixation conditions, antigen retrieval methods, and antibody dilutions to account for tissue-specific variables that may affect antigen detection.

Functional studies benefit from tissue-specific conditional knockout models, which allow precise temporal and spatial control over METTL21A deletion . This approach enables researchers to examine tissue-specific phenotypes while avoiding potential developmental complications associated with global knockouts. When analyzing these models, comprehensive phenotyping should include histological examination, expression analysis of known METTL21A targets, and functional assays relevant to the tissue being studied.

For cancer-related investigations, comparing METTL21A expression between normal and malignant tissues provides critical insights . Tissue microarrays enable high-throughput screening across multiple patient samples, facilitating correlation analyses between METTL21A expression and clinical parameters such as tumor grade, stage, and patient survival . These approaches collectively provide a comprehensive understanding of METTL21A's tissue-specific functions.

How can researchers investigate the relationship between METTL21A and HSP70 family members?

Investigating the relationship between METTL21A and HSP70 family members requires integrated approaches combining biochemical, cellular, and functional analyses. Co-immunoprecipitation assays using METTL21A antibodies represent a fundamental technique for detecting physical interactions between METTL21A and specific HSP70 proteins (HSPA1, HSPA2, HSPA5, HSPA6, and HSPA8) . These experiments should include appropriate controls to confirm specificity, such as IgG controls and reciprocal immunoprecipitations.

For mapping specific interaction domains, researchers can employ truncation or deletion mutants of both METTL21A and HSP70 proteins. This approach helps identify critical regions required for binding and subsequent methylation. In vitro binding assays using purified recombinant proteins provide complementary evidence for direct interactions, while analytical techniques like isothermal titration calorimetry or surface plasmon resonance offer quantitative measurements of binding affinities between METTL21A and different HSP70 family members.

Mass spectrometry analysis represents a powerful tool for identifying and characterizing specific methylation sites on HSP70 proteins . This approach has successfully mapped METTL21A-mediated trimethylation to specific lysine residues: 'Lys-561' in HSPA1, 'Lys-564' in HSPA2, 'Lys-585' in HSPA5, 'Lys-563' in HSPA6, and 'Lys-561' in HSPA8 . Functional studies examining how these modifications affect HSP70 chaperone activity, substrate binding, or ATPase activity provide critical insights into the biological significance of METTL21A-mediated methylation in cellular contexts.

What technical considerations are important when using recombinant METTL21A proteins?

Affinity tags facilitate purification but may influence protein function. Common tags include polyhistidine (His-tag), as demonstrated in the sequence: "MGSSHHHHHHSSGLVPRGSHMGST..." . While convenient for purification, researchers should consider whether to retain or remove tags for downstream applications, particularly when studying enzymatic activity or protein-protein interactions.

Protein quality assessment is essential before functional studies. SDS-PAGE analysis can confirm size and purity, while mass spectrometry provides more detailed characterization . For functional recombinant METTL21A, enzymatic activity should be verified through methyltransferase assays using known substrates like HSP70 family members .

Storage conditions significantly impact protein stability and activity. Recombinant METTL21A should typically be stored in buffer systems that maintain native conformation, often containing stabilizing agents like glycerol. Aliquoting prevents repeated freeze-thaw cycles that may compromise protein integrity. Before using in critical experiments, researchers should verify that the recombinant protein retains its methyltransferase activity after storage.

What are the potential roles of METTL21A beyond its known function in HSP70 methylation?

While METTL21A's role in HSP70 family protein methylation is well-established, emerging research suggests broader functional implications beyond this canonical activity. Recent studies investigating METTL21A in cancer contexts have revealed potential tumor suppressor functions, particularly in pancreatic ductal adenocarcinoma (PDAC) . This unexpected role suggests METTL21A may influence cellular signaling pathways beyond direct HSP70 modification, potentially affecting cell proliferation, apoptosis, or differentiation programs.

The dramatic acceleration of PDAC progression in Mettl21a knockout mouse models points to complex downstream effects that may involve multiple cellular pathways . These findings raise questions about whether METTL21A might target additional, currently unidentified substrates beyond HSP70 family members. Comprehensive proteomics approaches combining immunoprecipitation with mass spectrometry represent promising strategies to identify novel METTL21A interacting partners and potential substrates.

Interestingly, despite high expression in testes, METTL21A appears dispensable for mouse spermatogenesis and male fertility, as demonstrated in knockout studies . This unexpected finding suggests either functional redundancy with other methyltransferases or context-specific roles that become apparent only under particular physiological or stress conditions. Future research should explore METTL21A's potential functions under various cellular stresses, such as heat shock, oxidative stress, or proteotoxic conditions, where HSP70 proteins play crucial roles in maintaining protein homeostasis.

How does METTL21A expression correlate with clinical outcomes in different cancer types?

The relationship between METTL21A expression and clinical outcomes appears complex and potentially cancer-type specific. In pancreatic ductal adenocarcinoma (PDAC), meta-analysis of publicly available gene expression datasets has revealed that METTL21A is significantly downregulated in tumor tissue compared to normal pancreatic tissue . Furthermore, reduced METTL21A expression correlates with poor patient survival in PDAC, suggesting its potential value as a prognostic biomarker .